Generic name: ALISKIREN HEMIFUMARATE 150mg, AMLODIPINE BESYLATE 5mg
Dosage form: tablet, film coated
Drug class: Miscellaneous antihypertensive combinations
Medically reviewed by Drugs.com. Last updated on Dec 13, 2021.
2.1 General Considerations
The recommended initial once-daily dose of Tekamlo is 150 mg/5 mg. Titrate as needed to a maximum of 300 mg/10 mg.
The blood pressure lowering effects are largely attained within 1 to 2 weeks. If blood pressure remains uncontrolled after 2 to 4 weeks of therapy, titrate the dose to a maximum of Tekamlo 300 mg/10 mg once daily.
2.2 Add-on Therapy
Use Tekamlo for patients not adequately controlled with aliskiren alone or amlodipine besylate (or another dihydropyridine calcium channel blocker) alone.
Switch a patient who experiences dose-limiting adverse reactions on either component alone to Tekamlo containing a lower dose of that component in combination with the other to achieve similar blood pressure reductions.
2.3 Replacement Therapy
Switch patients receiving aliskiren and amlodipine besylate from separate tablets to a single tablet of Tekamlo containing the same component doses. When substituting for individual components, increase the dose of one or both of the components if blood pressure control has not been satisfactory.
More about Tekamlo (aliskiren / amlodipine)
- Side effects
- Drug interactions
- During pregnancy
- Drug images
- Drug class: miscellaneous antihypertensive combinations
- FDA approval history
Related treatment guides
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.